APGEApogee Therapeutics, Inc.
- GlobeNewswire
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 ...
- PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRBG, RMAX, GBCS, and APGE
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- PR Newswire
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws... ...
- PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--AVB, APGE, TMHC, and LPRO
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- PR Newswire
Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws... ...
- PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- Analyst Upgrades
Stifel Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135
Stifel analyst Akash Tewari downgrades Apogee Therapeutics from Buy to Hold and raises the price target from $133 to $135. ...
- Analyst Upgrades
TD Cowen Downgrades Apogee Therapeutics to Hold
TD Cowen analyst Tyler Van Buren downgrades Apogee Therapeutics from Buy to Hold. ...
- Analyst Upgrades
Guggenheim Downgrades Apogee Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Apogee Therapeutics from Buy to Neutral. ...
- Analyst Upgrades
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think of these stocks. ...
- Analyst Upgrades
Mizuho Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135
Mizuho analyst Joseph Catanzaro downgrades Apogee Therapeutics from Outperform to Neutral and raises the price target from $110 to $135. ...
- Analyst Upgrades
Deutsche Bank Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135
Deutsche Bank analyst David Hoang downgrades Apogee Therapeutics from Buy to Hold and raises the price target from $116 to $135. ...
- Analyst Upgrades
This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgraded IBM,. See analyst ratings. ...
- Analyst Upgrades
Citigroup Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135
Citigroup analyst Geoff Meacham downgrades Apogee Therapeutics from Buy to Neutral and raises the price target from $125 to $135. ...
- Analyst Upgrades
RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $135
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Sector Perform and raises the price target from $97 to $135. ...
- Analyst Upgrades
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage. ...
- Analyst Upgrades
UBS Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135.11
UBS analyst Michael Yee downgrades Apogee Therapeutics from Buy to Neutral and raises the price target from $100 to $135.11. ...
- Analyst Upgrades
This Zions Bancorp Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Wall Street analysts changed ratings for PRIM, ZION, and APGE. Check out analysts' views on these stocks. Photo via Shutterstock. ...
- Analyst Upgrades
This Zions Bancorp Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Wall Street analysts changed ratings for PRIM, ZION, and APGE. Check out analysts' views on these stocks. Photo via Shutterstock. ...
- Analyst Upgrades
Wedbush Downgrades Apogee Therapeutics to Neutral, Maintains Price Target to $135
Wedbush analyst David Nierengarten downgrades Apogee Therapeutics from Outperform to Neutral and maintains the price target from $135 to $135. ...
- PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE)
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- PR Newswire
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced... ...
- PR Newswire
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) ("Apogee") today announced they have entered into a definitive agreement under which... ...
- Reuters
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. ...
- PR Newswire
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) ("Apogee") today announced they have entered into a definitive agreement under which... ...